Targeting the complement system

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 5, 1999, Pages 557-562

  Marsh, James E ^b   Pratt, Julian R ^b   Sacks, Steven H ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT INHIBITOR;

CANCER; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOLYSIS; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; ISCHEMIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; EXTRACORPOREAL CIRCULATION; GLOMERULONEPHRITIS; HUMANS; NEOPLASMS, EXPERIMENTAL; ORGAN TRANSPLANTATION; REPERFUSION INJURY;

EID: 0033404590     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199909000-00004     Document Type: Review

References (33)

1. 1 Bordet J. The mode of action of preventive serums [in French]. Ann Inst Pasteur 1896; 10:193-219.
2. 2 Kirschfink M. Controlling the complement system in inflammation [Review]. Immunopharmacology 1997; 38:51-62.
3. 3 Christiansen D, Milland J, Thorley BR, McKenzie IF, Mottram PL, Purcell LJ, Loveland BE. Engineering of recombinant soluble CD46: an inhibitor of complement activation. Immunology 1996; 87:348-354.
4. 4 Christiansen D, Milland J, Thorley BR, McKenzie IF, Loveland BE. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur J Immunol 1996; 26:578-585.
5. 5 Pratt JR, Harmer AW, Levin J, Sacks SH. Influence of complement on the allospecific antibody response to a primary vascularized organ graft. Eur J Immunol 1997; 27:2848-2853.
6. 6 Birmingham DJ. Erythrocyte complement receptors [Review]. Crit Rev Immunol 1995; 15:133-154.
7. 7 Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998; 92:1661-1667. This excellent article describes the biological effects of a new class of complement inhibitor generated from a clone of phage-displayed random peptide library that was screened for binding to C3b. This peptide may have improved oral bioavailability.
8. 8 Kilgore KS, Naylor KB, Tanhehco EJ, Park JL, Booth EA, Washington RA, Lucchesi BR. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther 1998; 285:987-994.
9. 9 Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97:2259-2267. This very useful study highlights the role of the terminal complement components in the generation of ischaemia/reperfusion injury. An impressive 60% reduction in myocardial infarct size was noted in rats treated with an anti-C5 antibody.
10. 10 Zhang HF, Yu J, Bajwa E, Morrison SL, Tomlinson S. Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest 1999; 103:55-61. A new approach to targeted complement therapy is discussed. The authors demonstrated that it is possible to obtain tissue-specific complement inhibition in vitro by coupling a complement regulatory molecule with antigen-combining sites of antibody.
11. 11 Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh HC Jr, Carson GR, et al. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Phys 1990; 103:64-72.
12. 12 Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, Brauer RB, et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996; 98:503-512.
13. 13 Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, Hechtman HB, Carroll MC. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996; 183:2343-2348.
14. 14 Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, Moore FD Jr. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol 1992; 149:1723-1728.
15. 15 Kimura T, Andoh A, Fujiyama Y, Saotome T, Bamba T. A blockade of complement activation prevents rapid intestinal ischaemia-reperfusion injury by modulating mucosal mast cell degranulation in rats. Clin Exp Immunol 1998; 111:484-490. This interesting article suggests that the early phases of intestinal ischaemia/ reperfusion injury are mediated primarily through the action of complement.
16. 16 Vasthare US, Barone FC, Sarau HM, Rosenwasser RH, DiMartino M, Young WF, Tuma RF. Complement depletion improves neurological function in cerebral ischemia. Brain Res Bull 1998; 45:413-419.
17. 17 Pratt JR, Hibbs MJ, Laver AJ, Smith RA, Sacks SH. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 1996; 149:2055-2066.
18. 18 Lehmann TG, Koeppel TA, Kirschfink M, Gebhard MM, Herfarth C, Otto G, Post S. Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation. Transplantation 1998; 66:717-722.
19. 19 Pierre AF, Xavier AM, Liu M, Cassivi SD, Lindsay TF, Marsh HC, et al. Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function. Transplantation 1998; 66:723-732.
20. 20 Schmid RA, Zollinger A, Singer T, Hillinger S, Leon-Wyss JR, Schob OM, et al. Effect of soluble complement receptor type 1 on reperfusion edema and neutrophil migration after lung allotransplantation in swine. J Thorac Cardiovasc Surg 1998; 116:90-97.
21. 21 Pagtalunan ME, Olson JL, Tilney NL, Meyer TW. Late consequences of acute ischemic injury to a solitary kidney. J Am Soc Nephrol 1999; 10:366-373. This important paper demonstrates the long-term consequences of ischaemic injury to a kidney. This highlights the potential importance of therapeutic intervention to prevent ischaemia/reperfusion injury in a transplanted kidney.
22. 22 Yu J, Caragine T, Chen S, Morgan BP, Frey AB, Tomlinson S. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin Exp Immunol 1999; 115:13-18. This interesting study demonstrates the protective influence of complement regulatory molecules to cancer cells, which may have implications when immunotherapy is designed.
23. 23 Blok VT, Daha MR, Tijsma O, Harris CL, Morgan BP, Fleuren GJ, Gorter A. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998; 160:3437-3443. This is an example of targeted complement inhibition in cancer cells. A tumour-specific antibody was combined with an antibody to a complement regulatory protein to increase the target cell susceptibility to lysis.
24. 24 Hebert MJ, Takano T, Papayianni A, Rennke HG, Minto A, Salant DJ, et al. Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrol Dial Transplant 1998; 13:2799-2803.
25. 25 Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3-and C4-deficient mice. Clin Exp Immunol 1997; 110:403-409.
26. 26 Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, Holers VM. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med 1998; 188:1321-1331. This excellent article describes the first use of a trangenic mouse over-expressing a complement regulatory protein in a disease model. These mice were protected from nephrotoxic serum nephritis. In addition, these mice demonstrated no long-term phenotypic abnormalities, indicating that continued complement inhibition is feasible and effective.
27. 27 Schiller B, He C, Salant DJ, Lim A, Alexander JJ, Quigg RJ. Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis. J Exp Med 1998; 188:1353-1358. This interesting article demonstrates that complement regulation is important in the generation of Heymann nephritis.
28. 28 Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 1999; 10:69-76.
29. 29 Morita Y, Nomura A, Yuzawa Y, Nishikawa K, Hotta N, Shimizu F, Matsuo S. The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1997; 8:1363-1372.
30. 30 Sasaki O, Zhou W, Miyazaki M, Abe K, Koji T, Verroust P, et al. Intraglomerular C3 synthesis in rats with passive Heymann nephritis. Am J Pathol 1997; 151:1249-1256.
31. 31 Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH. Contribution of renal secreted complement C3 to the circulating pool in humans [Abstract]. J Immunol 1999; 162:4336-4341. The authors demonstrate that local production of C3 by a renal transplant is greater than previously thought, and that local synthesis is specifically upregulated during rejection episodes.
32. 32 Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome [see comments]. Kidney Int 1998; 53:836-844.
33. 33 Lazar HL, Hamasaki T, Bao Y, Rivers S, Bernard SA, Shemin RJ. Soluble complement receptor type I limits damage during revascularization of ischemic myocardium. Ann Thorac Surg 1998; 65:973-977.